Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease
Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease
复制标题
DOI：
10.1038/sj.bmt.1705696
复制
发表时间：
2007-07-01
影响因子：
4.8
通讯作者：
Potter, M.
中科院分区：
文献类型：
--
作者：
Dignan, F.;Gujral, D.;Potter, M.
静脉闭塞性疾病（VOD）是同种异体干细胞移植（SCT）的常见高危并发症。去纤维蛋白多核苷酸最近已成功用于治疗这种疾病。我们报告了 58 名接受去纤维蛋白多核苷酸预防但未同时使用肝素的患者。没有患者符合巴尔的摩 VOD 标准，也没有患者在 SCT 后 100 天内死于该疾病。该组中没有人出现继发于去纤维蛋白多核苷酸的出血并发症。这些观察结果表明，单独使用去纤维蛋白多核苷酸进行预防可能会降低 SCT 后 VOD 的发生率，尽管需要进行随机对照试验来进一步评估其作用。
Veno-occlusive disease (VOD) is a common and high-risk complication of allogeneic stem cell transplantation (SCT). Defibrotide has recently been used successfully to treat the disorder. We report on 58 patients who received defibrotide prophylaxis without concurrent heparin. No patients fulfilled the Baltimore criteria for VOD or died of the condition within 100 days of SCT. None of this group developed haemorrhagic complications secondary to defibrotide. These observations suggest that prophylaxis with defibrotide alone may reduce the incidence of VOD post-SCT although a randomised controlled trial is warranted to further evaluate its role.